Amgen Acquires UK- based Dark Blue Therapeutics in 840M USD Deal
Amgen’s acquisition of Dark Blue Therapeutics, adds a first-in-class protein degrader programme targeting MLLT1/3-driven acute myeloid leukemia to strengthen its early-stage oncology pipeline.<br />
Clinical Oncology Research | 07/01/2026 | By News Bureau | 108
Astellas and Japanese Foundation for Cancer Research to Accelerate Clinical Oncology Research
Through this collaboration, Astellas is committed to strengthening translational science and clinical research in order to deliver innovative new medicines.
Clinical Oncology Research | 04/04/2025 | By Aishwarya | 389
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy